https://m2.mtmt.hu/ hun 2026-05-26 15:47 JournalArticle 34095902 VALIDATED true Export Date: 24 April 2024 CODEN: BIPHE Correspondence Address: Szénási, G.; Institute of Translational Medicine, Nagyvárad tér 4, Hungary; email: szenasi.gabor@med.semmelweis-univ.hu 0 false 2026-05-23T03:36:57.993+0000 2023-12-14T08:46:13.233+0000 2023-08-15T12:27:29.211+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Pintér Ibolya Katalin (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2024-12-18T11:08:12.294+0000 2023-12-14T08:46:13.493+0000 true 10062062 Gere Tamásné /api/admin/10062062 Admin Gere Tamásné (SE_KK_Admin5_GT, admin) true 10062062 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Bakos, Tamás true true /api/journal/732 REVIEWED BIOMEDICINE & PHARMACOTHERAPY 0753-3322 1950-6007 true false 732 false 732 true 0753-3322 1950-6007 Journal FOREIGN 166 115294 115294 8 2023 Funding 2030020 /api/funding/2030020 (KDP-14-3/PALY-2021) false true Funding 2030021 /api/funding/2030021 European Union Horizon 2020 projects(825828) false true Funding 2030022 /api/funding/2030022 European Union Horizon 2020 projects(952520) false true Funding 2030023 /api/funding/2030023 (2020-1.1.6-JOVO-2021-00013) false true Funding 2030024 /api/funding/2030024 (2020-1.1.6-JOVO-2021-00010.2020) false true true true 2023 true true true false true false GOLD 2026-05-23 true https://doi.org/10.1016/j.biopha.2023.115294 2 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 2 1 1 1 0 3 3 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 1 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 1 2 1 D1 false 10024742,10027489 false false false 2023-08-20T11:28:40.525+0000 Elméleti Egészségtudományok Intézete (ME / ETK); Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Transzlációs Medicina Intézet (SE / AOK / I) 4 29 3 4 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 109589293 /api/authorship/109589293 Bakos, Tamás [Bakos, Tamás (Immunológia), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 1 0.25 true false false Author 10070223 /api/author/10070223 Bakos Tamás (Immunológia) Bakos Tamás true true Bakos Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 113250665 /api/authorship/113250665 Kozma, Gergely [Kozma, Gergely Tibor (Immunológia, Mole...), szerző] 2 0.0 false false Author 10024742 /api/author/10024742 Kozma Gergely Tibor (Immunológia, Molekuláris biológia) Kozma Gergely Tibor true 10024742 true Kozma Gergely true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109589295 /api/authorship/109589295 Szebeni, János** [Szebeni, János (Klinikai orvostud...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Elméleti Egészségtudományok Intézete (ME / ETK) 3 0.25 false true false Author 10003266 /api/author/10003266 Szebeni János (Klinikai orvostudomány, immunológia, nanomedicina) Szebeni János true 10003266 true Szebeni János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109589296 /api/authorship/109589296 Szénási, Gábor ✉ [Szénási, Gábor (kórélettan), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 4 0.25 false true true Author 10027489 /api/author/10027489 Szénási Gábor (kórélettan) Szénási Gábor true 10027489 true Szénási Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 24255951 /api/publicationidentifier/24255951 DOI: 10.1016/j.biopha.2023.115294 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.biopha.2023.115294 https://doi.org/10.1016/j.biopha.2023.115294 false true PublicationIdentifier 24465882 /api/publicationidentifier/24465882 WoS: 001063304800001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001063304800001 https://www.webofscience.com/wos/woscc/full-record/001063304800001 false true PublicationIdentifier 24283127 /api/publicationidentifier/24283127 Scopus: 85166909281 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85166909281 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85166909281 true true PublicationIdentifier 24465883 /api/publicationidentifier/24465883 PubMed: 37567071 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 37567071 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37567071&dopt=Abstract false true SjrRating 11397167 /api/sjrrating/11397167 sjr:D1 (2023) Scopus - Medicine (miscellaneous) BIOMEDICINE & PHARMACOTHERAPY 0753-3322 1950-6007 237 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true D1 DIRECT true true Reference 44358288 /api/reference/44358288 1. Tisoncik 2012: Into the eye of the cytokine storm., Microbiol. Mol. Biol. Rev., 76, p. 16, DOI: 10.1128/MMBR.05015-11 1 10.1128/MMBR.05015-11 false true Reference 44358289 /api/reference/44358289 2. Radke 2012: Induced cytokine response of human PMBC-cultures: correlation of gene expression and secretion profiling and the effect of cryopreservation., Cell. Immunol., 272, p. 144, DOI: 10.1016/j.cellimm.2011.10.018 2 10.1016/j.cellimm.2011.10.018 false true Reference 44358290 /api/reference/44358290 3. Zhang 2007: Cytokines, inflammation, and pain., Int. Anesth. Clin., 45, p. 27, DOI: 10.1097/AIA.0b013e318034194e 3 10.1097/AIA.0b013e318034194e false true Reference 44358291 /api/reference/44358291 4. Yiu 2012: Dynamics of a cytokine storm., PLoS One, 7, DOI: 10.1371/journal.pone.0045027 4 10.1371/journal.pone.0045027 false true Reference 44358292 /api/reference/44358292 5. Potter 2018: Analysis of pro-inflammatory cytokine and type II interferon induction by nanoparticles., Methods Mol. Biol., 1682, p. 173, DOI: 10.1007/978-1-4939-7352-1_15 5 10.1007/978-1-4939-7352-1_15 false true Reference 44358293 /api/reference/44358293 6. Fajgenbaum 2020: Cytokine storm., N. Engl. J. Med., 383, p. 2255, DOI: 10.1056/NEJMra2026131 6 10.1056/NEJMra2026131 false true Reference 44358294 /api/reference/44358294 7. Karki 2021: The 'cytokine storm': molecular mechanisms and therapeutic prospects., Trends Immunol., 42, p. 681, DOI: 10.1016/j.it.2021.06.001 7 10.1016/j.it.2021.06.001 false true Reference 44358295 /api/reference/44358295 8. Jafarzadeh 2020: Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions., Life Sci., 257, DOI: 10.1016/j.lfs.2020.118102 8 10.1016/j.lfs.2020.118102 false true Reference 44358296 /api/reference/44358296 9. Olajide 2021: Induction of exaggerated cytokine production in human peripheral blood mononuclear cells by a recombinant SARS-CoV-2 spike glycoprotein S1 and its inhibition by dexamethasone., Inflammation, 44, p. 1865, DOI: 10.1007/s10753-021-01464-5 9 10.1007/s10753-021-01464-5 false true Reference 44358297 /api/reference/44358297 10. Montazersaheb 2022: COVID-19 infection: an overview on cytokine storm and related interventions., Virol. J., 19, p. 92, DOI: 10.1186/s12985-022-01814-1 10 10.1186/s12985-022-01814-1 false true Reference 44358298 /api/reference/44358298 11. Ramatillah 2022: Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination., PLoS One, 17, DOI: 10.1371/journal.pone.0262438 11 10.1371/journal.pone.0262438 false true Reference 44358299 /api/reference/44358299 12. Hu 2021: Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19., Cytokine Growth Factor Rev., 58, p. 30, DOI: 10.1016/j.cytogfr.2020.08.001 12 10.1016/j.cytogfr.2020.08.001 false true Reference 44358300 /api/reference/44358300 13. Hu 2021: The cytokine storm and COVID-19., J. Med. Virol., 93, p. 250, DOI: 10.1002/jmv.26232 13 10.1002/jmv.26232 false true Reference 44358301 /api/reference/44358301 14. Yu 2020: Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition., Blood, 136, p. 2080, DOI: 10.1182/blood.2020008248 14 10.1182/blood.2020008248 false true Reference 44358302 /api/reference/44358302 15. Huber 2021: Systemic inflammation and complement activation parameters predict clinical outcome of severe SARS-CoV-2 infections., Viruses, 13, DOI: 10.3390/v13122376 15 10.3390/v13122376 false true Reference 44358303 /api/reference/44358303 16. Lo 2022: SARS-CoV-2 triggers complement activation through interactions with heparan sulfate., Clin. Transl. Immunol., 11, DOI: 10.1002/cti2.1413 16 10.1002/cti2.1413 false true Reference 44358304 /api/reference/44358304 17. Ali 2021: Lectin pathway mediates complement activation by SARS-CoV-2 proteins., Front. Immunol., 12, DOI: 10.3389/fimmu.2021.714511 17 10.3389/fimmu.2021.714511 false true Reference 44358305 /api/reference/44358305 18. Ma 2021: Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection., Sci. Immunol., 6, DOI: 10.1126/sciimmunol.abh2259 18 10.1126/sciimmunol.abh2259 false true Reference 44358306 /api/reference/44358306 19. Dezsi 2022: A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor., Geroscience, 44, p. 597, DOI: 10.1007/s11357-021-00495-y 19 10.1007/s11357-021-00495-y false true Reference 44358307 /api/reference/44358307 20. Zhang 2023: Local complement contributes to pathogenic activation of lung endothelial cells in SARS-CoV-2 infection., Am. J. Respir. Cell Mol. Biol., DOI: 10.1165/rcmb.2022-0373OC 20 10.1165/rcmb.2022-0373OC false true Reference 44358308 /api/reference/44358308 21. Ronnelid 2008: Immune complex-mediated cytokine production is regulated by classical complement activation both in vivo and in vitro., Adv. Exp. Med. Biol., 632, p. 187 21 false true Reference 44358309 /api/reference/44358309 22. Ehrnstrom 2020: TLR8 and complement C5 induce cytokine release and thrombin activation in human whole blood challenged with Gram-positive bacteria., J. Leukoc. Biol., 107, p. 673, DOI: 10.1002/JLB.3A0120-114R 22 10.1002/JLB.3A0120-114R false true Reference 44358310 /api/reference/44358310 23. Fujimura 2022: COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm., Int. J. Hematol., 115, p. 457, DOI: 10.1007/s12185-022-03324-w 23 10.1007/s12185-022-03324-w false true Reference 44358311 /api/reference/44358311 24. Kozma 2021: Mini-Factor H modulates complement-dependent IL-6 and IL-10 release in an immune cell culture (PBMC) model: potential benefits against cytokine storm., Front. Immunol., 12, DOI: 10.3389/fimmu.2021.642860 24 10.3389/fimmu.2021.642860 false true Reference 44358312 /api/reference/44358312 25. Sato 2003: Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A., J. Immunol., 171, p. 417, DOI: 10.4049/jimmunol.171.1.417 25 10.4049/jimmunol.171.1.417 false true Reference 44358313 /api/reference/44358313 26. Zhang 2007: Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo., Blood, 110, p. 228, DOI: 10.1182/blood-2006-12-063636 26 10.1182/blood-2006-12-063636 false true Reference 44358314 /api/reference/44358314 27. Brown 2006: Dectin-1: a signalling non-TLR pattern-recognition receptor., Nat. Rev. Immunol., 6, p. 33, DOI: 10.1038/nri1745 27 10.1038/nri1745 false true Reference 44358315 /api/reference/44358315 28. Goodridge 2007: Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells., J. Immunol., 178, p. 3107, DOI: 10.4049/jimmunol.178.5.3107 28 10.4049/jimmunol.178.5.3107 false true Reference 44358316 /api/reference/44358316 29. Haque 2017: Autologous serum supplement favours in vitro regenerative paracrine factors synthesis., Cell Prolif., 50, DOI: 10.1111/cpr.12354 29 10.1111/cpr.12354 false true Reference 44358317 /api/reference/44358317 30. Ehnert 2011: Autologous serum improves yield and metabolic capacity of monocyte-derived hepatocyte-like cells: possible implication for cell transplantation., Cell Transpl., 20, p. 1465, DOI: 10.3727/096368910X550224 30 10.3727/096368910X550224 false true Reference 44358318 /api/reference/44358318 31. Huber-Lang 2014: Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice., J. Immunol., 192, p. 5324, DOI: 10.4049/jimmunol.1400341 31 10.4049/jimmunol.1400341 false true Reference 44358319 /api/reference/44358319 32. Wang 2010: Regulation of IL-8 production by complement-activated product, C5a, in vitro and in vivo during sepsis., Clin. Immunol., 137, p. 157, DOI: 10.1016/j.clim.2010.05.012 32 10.1016/j.clim.2010.05.012 false true Reference 44358320 /api/reference/44358320 33. Cheng 2012: Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs., Eur. J. Immunol., 42, p. 993, DOI: 10.1002/eji.201142057 33 10.1002/eji.201142057 false true Reference 44358321 /api/reference/44358321 34. Hellerud 2017: Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis., J. Intensive Care, 5, p. 21, DOI: 10.1186/s40560-017-0217-0 34 10.1186/s40560-017-0217-0 false true Reference 44358322 /api/reference/44358322 35. Bosmann 2012: Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis., Adv. Exp. Med. Biol., 946, p. 147, DOI: 10.1007/978-1-4614-0106-3_9 35 10.1007/978-1-4614-0106-3_9 false true Reference 44358323 /api/reference/44358323 36. Magro 2020: COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking., Virus Res., 286, DOI: 10.1016/j.virusres.2020.198070 36 10.1016/j.virusres.2020.198070 false true Reference 44358324 /api/reference/44358324 37. Chinta 2023: COVID-19 therapy and vaccination: a clinical narrative review., Drugs Context, 12, DOI: 10.7573/dic.2022-7-2 37 10.7573/dic.2022-7-2 false true Reference 44358325 /api/reference/44358325 38. Ray 2023: Prognostic significance of the coagulation and complement systems in critical COVID-19 infection., Prague Med. Rep., 124, p. 77, DOI: 10.14712/23362936.2023.7 38 10.14712/23362936.2023.7 false true Reference 44358326 /api/reference/44358326 39. Rehman 2023: Sustained Response to eculizumab in a patient with COVID-19-associated acute thrombotic microangiopathy of the allograft kidney: a case report., Transpl. Proc., DOI: 10.1016/j.transproceed.2023.03.072 39 10.1016/j.transproceed.2023.03.072 false true Reference 44358327 /api/reference/44358327 40. Ruggenenti 2021: Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: retrospective cohort study., PLoS One, 16, DOI: 10.1371/journal.pone.0261113 40 10.1371/journal.pone.0261113 false true Reference 44358328 /api/reference/44358328 41. Leone 2022: Case report: tackling complement hyperactivation with eculizumab in atypical hemolytic uremic syndrome triggered by COVID-19., Front. Pharm., 13, DOI: 10.3389/fphar.2022.842473 41 10.3389/fphar.2022.842473 false true /api/publication/34095902 Bakos Tamás et al. Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19. (2023) BIOMEDICINE & PHARMACOTHERAPY 0753-3322 1950-6007 166<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10070223"><a href="/gui2/?type=authors&mode=browse&sel=10070223" target="_blank">Bakos Tamás (<span class="authorship-author-name">Bakos Tamás</span> <span class="authorAux-mtmt"> Immunológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024742"><a href="/gui2/?type=authors&mode=browse&sel=10024742" target="_blank">Kozma Gergely (<span class="authorship-author-name">Kozma Gergely Tibor</span> <span class="authorAux-mtmt"> Immunológia, Molekuláris biológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003266"><a href="/gui2/?type=authors&mode=browse&sel=10003266" target="_blank">Szebeni János^** (<span class="authorship-author-name">Szebeni János</span> <span class="authorAux-mtmt"> Klinikai orvostudomány, immunológia, nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Miskolci Egyetem">ME</span>/<span title="Egészségtudományi Kar ">ETK</span>/Elméleti Egészségtudományok Intézete</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027489"><a href="/gui2/?type=authors&mode=browse&sel=10027489" target="_blank">Szénási Gábor ✉ (<span class="authorship-author-name">Szénási Gábor</span> <span class="authorAux-mtmt"> kórélettan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34095902" target="_blank">Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19</a></div> <div> <span class="journal-title">BIOMEDICINE & PHARMACOTHERAPY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0753-3322">0753-3322</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1950-6007">1950-6007</a>)</span>: <span class="journal-volume">166</span> <span class="page"> Paper 115294. 8 p. </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.biopha.2023.115294" target="_blank" href="https://doi.org/10.1016/j.biopha.2023.115294"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001063304800001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001063304800001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85166909281" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85166909281"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="37567071" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37567071&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 2</span> | Független: 1 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 1 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34095902&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 3 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34095902</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (KDP-14-3/PALY-2021), European Union Horizon 2020 projects(825828), European Union Horizon 2020 projects(952520), (2020-1.1.6-JOVO-2021-00013), (2020-1.1.6-JOVO-2021-00010.2020) </div> <div class="lastModified">Utolsó módosítás: 2023.12.14. 09:46 Gere Tamásné (SE_KK_Admin5_GT, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 24 April 2024 CODEN: BIPHE Correspondence Address: Szénási, G.; Institute of Translational Medicine, Nagyvárad tér 4, Hungary; email: szenasi.gabor@med.semmelweis-univ.hu</pre> </div></div>